Increasing evidence that the risks of rhAPC may outweigh its benefits

Intensive Care Med. 2007 Mar;33(3):396-9. doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anti-Infective Agents / adverse effects*
  • Drug-Related Side Effects and Adverse Reactions
  • Hemorrhage / chemically induced*
  • Hemorrhage / epidemiology
  • Hospital Mortality
  • Humans
  • Incidence
  • Infusions, Intravenous
  • Protein C / adverse effects*
  • Recombinant Proteins / adverse effects
  • Risk Assessment
  • Sepsis / drug therapy*
  • Sepsis / mortality

Substances

  • Anti-Infective Agents
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated